Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!

Range Low Price High Price Comment
30 days $5.84 $8.40 Friday, 10th May 2024 VERV stock ended at $6.01. This is 5.50% less than the trading day before Thursday, 9th May 2024. During the day the stock fluctuated 9.35% from a day low at $5.88 to a day high of $6.43.
90 days $5.84 $19.34
52 weeks $5.84 $21.42

Historical Verve Therapeutics, Inc. prices

Date Open High Low Close Volume
Mar 03, 2022 $31.43 $31.96 $28.34 $28.67 435 000
Mar 02, 2022 $30.76 $31.72 $29.98 $31.18 320 600
Mar 01, 2022 $32.81 $33.64 $30.61 $30.75 546 400
Feb 28, 2022 $30.00 $33.28 $30.00 $32.65 818 900
Feb 25, 2022 $29.14 $31.66 $27.83 $30.76 1 030 600
Feb 24, 2022 $25.76 $29.28 $25.18 $29.00 670 400
Feb 23, 2022 $27.62 $28.07 $26.73 $26.96 424 000
Feb 22, 2022 $26.57 $27.90 $26.57 $27.30 493 900
Feb 18, 2022 $28.02 $28.47 $25.49 $26.76 695 400
Feb 17, 2022 $29.77 $30.13 $27.32 $28.02 464 000
Feb 16, 2022 $31.62 $31.62 $29.83 $30.21 295 100
Feb 15, 2022 $30.27 $31.98 $29.47 $31.97 576 500
Feb 14, 2022 $31.06 $31.39 $29.52 $29.59 424 200
Feb 11, 2022 $30.54 $32.98 $30.12 $30.94 463 300
Feb 10, 2022 $30.34 $32.47 $29.88 $30.50 533 500
Feb 09, 2022 $28.70 $31.41 $28.70 $31.34 456 000
Feb 08, 2022 $27.80 $29.45 $27.38 $28.62 381 400
Feb 07, 2022 $27.42 $28.31 $26.99 $27.80 423 300
Feb 04, 2022 $25.95 $27.52 $24.92 $26.98 489 000
Feb 03, 2022 $27.56 $28.73 $26.17 $26.26 437 100
Feb 02, 2022 $29.60 $29.95 $27.25 $28.04 579 500
Feb 01, 2022 $29.18 $30.15 $27.54 $28.99 767 000
Jan 31, 2022 $28.96 $29.77 $28.05 $28.82 952 500
Jan 28, 2022 $26.32 $28.53 $24.75 $28.44 904 300
Jan 27, 2022 $30.48 $32.00 $26.56 $26.57 864 000
Click to get the best stock tips daily for free!

About Verve Therapeutics, Inc.

Verve Therapeutics. Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with... VERV Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT